索塔格利弗洛辛:在心力衰竭中有效性,安全性和潜在的治疗应用
1Department of Pharmacy Practice and Administration, School of Pharmacy and Physician Assistant Studies, University of Saint Joseph, West Hartford, CT, USA.
The Annals of pharmacotherapy
|November 28, 2023
概括
索塔格利弗洛辛是一种双重SGLT1/SGLT2抑制剂,通过减少心血管事件,在心力衰竭 (HF) 管理方面表现有前途. 然而,与已建立的SGLT2抑制剂相比,其采用是不确定的,因为对比数据有限.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 索塔格利弗洛辛是-葡萄糖共载体 (SGLT) 1和SGLT2.2的第一个双抑制剂.
- 它为心力衰竭 (HF) 管理提供了一个新的治疗选择.
研究的目的:
- 评估sotagliflozin在高血压中药理学,临床疗效和安全性.
- 为了比较sotagliflozin的证据与现有的SGLT2抑制剂用于HF治疗.
主要方法:
- 在2012年1月至2023年9月的研究中,使用PubMed,MEDLINE和clinicaltrials.gov.gov进行文献搜索.
- 包括所有研究英语研究sotagliflozin的药理学,疗效或安全.
主要成果:
- 两项3期试验 (SOLOIST-WHF,SCORED) 显示,索塔格利弗洛辛在2型糖尿病 (T2DM) 患者中降低了心血管和HF事件.
- SOLOIST-WHF显示心血管和HF事件的统计显著下降 (HR=0.67).
- 在T2DM,CKD和心血管风险因素 (HR=0.74) 的患者中,SCORED显示心血管事件显著减少.
结论:
- 索塔格利弗洛辛扩大了HF治疗选择,但面临着具有更广泛数据的SGLT2抑制剂的竞争.
- 需要进一步的研究来澄清sotagliflozin与SGLT2抑制剂相比的益处,因为试验的局限性和缺乏直接比较.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:26Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
01:22Heart Failure Drugs: Diuretics
396
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
396
01:22Heart Failure Drugs: β-Blockers
342
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
01:23Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190